395 related articles for article (PubMed ID: 17039257)
1. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition.
Ohsawa Y; Hagiwara H; Nakatani M; Yasue A; Moriyama K; Murakami T; Tsuchida K; Noji S; Sunada Y
J Clin Invest; 2006 Nov; 116(11):2924-34. PubMed ID: 17039257
[TBL] [Abstract][Full Text] [Related]
2. An inhibitor of transforming growth factor beta type I receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy.
Ohsawa Y; Okada T; Nishimatsu S; Ishizaki M; Suga T; Fujino M; Murakami T; Uchino M; Tsuchida K; Noji S; Hinohara A; Shimizu T; Shimizu K; Sunada Y
Lab Invest; 2012 Aug; 92(8):1100-14. PubMed ID: 22584670
[TBL] [Abstract][Full Text] [Related]
3. Atelocollagen-mediated systemic administration of myostatin-targeting siRNA improves muscular atrophy in caveolin-3-deficient mice.
Kawakami E; Kinouchi N; Adachi T; Ohsawa Y; Ishimaru N; Ohuchi H; Sunada Y; Hayashi Y; Tanaka E; Noji S
Dev Growth Differ; 2011 Jan; 53(1):48-54. PubMed ID: 21261610
[TBL] [Abstract][Full Text] [Related]
4. Endoplasmic reticulum stress response in P104L mutant caveolin-3 transgenic mice.
Kuga A; Ohsawa Y; Okada T; Kanda F; Kanagawa M; Toda T; Sunada Y
Hum Mol Genet; 2011 Aug; 20(15):2975-83. PubMed ID: 21610159
[TBL] [Abstract][Full Text] [Related]
5. Caveolin-3 regulates myostatin signaling. Mini-review.
Ohsawa Y; Okada T; Kuga A; Hayashi S; Murakami T; Tsuchida K; Noji S; Sunada Y
Acta Myol; 2008 Jul; 27(1):19-24. PubMed ID: 19108573
[TBL] [Abstract][Full Text] [Related]
6. The Inhibitory Core of the Myostatin Prodomain: Its Interaction with Both Type I and II Membrane Receptors, and Potential to Treat Muscle Atrophy.
Ohsawa Y; Takayama K; Nishimatsu S; Okada T; Fujino M; Fukai Y; Murakami T; Hagiwara H; Itoh F; Tsuchida K; Hayashi Y; Sunada Y
PLoS One; 2015; 10(7):e0133713. PubMed ID: 26226340
[TBL] [Abstract][Full Text] [Related]
7. Altered caveolin-3 expression disrupts PI(3) kinase signaling leading to death of cultured muscle cells.
Smythe GM; Rando TA
Exp Cell Res; 2006 Sep; 312(15):2816-25. PubMed ID: 16814768
[TBL] [Abstract][Full Text] [Related]
8. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes.
Smythe GM; Eby JC; Disatnik MH; Rando TA
J Cell Sci; 2003 Dec; 116(Pt 23):4739-49. PubMed ID: 14600260
[TBL] [Abstract][Full Text] [Related]
9. Time-dependent expression of myostatin RNA transcript and protein in gastrocnemius muscle of mice after sciatic nerve resection.
Shao C; Liu M; Wu X; Ding F
Microsurgery; 2007; 27(5):487-93. PubMed ID: 17596894
[TBL] [Abstract][Full Text] [Related]
10. Targeting myostatin for therapies against muscle-wasting disorders.
Tsuchida K
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):487-94. PubMed ID: 18600566
[TBL] [Abstract][Full Text] [Related]
11. Prolonged absence of myostatin reduces sarcopenia.
Siriett V; Platt L; Salerno MS; Ling N; Kambadur R; Sharma M
J Cell Physiol; 2006 Dec; 209(3):866-73. PubMed ID: 16972257
[TBL] [Abstract][Full Text] [Related]
12. [Myostatin blockade therapy for muscular atrophy].
Sunada Y
Brain Nerve; 2011 Nov; 63(11):1271-7. PubMed ID: 22068480
[TBL] [Abstract][Full Text] [Related]
13. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C.
Bogdanovich S; McNally EM; Khurana TS
Muscle Nerve; 2008 Mar; 37(3):308-16. PubMed ID: 18041051
[TBL] [Abstract][Full Text] [Related]
14. The myostatin gene: physiology and pharmacological relevance.
Joulia-Ekaza D; Cabello G
Curr Opin Pharmacol; 2007 Jun; 7(3):310-5. PubMed ID: 17374508
[TBL] [Abstract][Full Text] [Related]
15. Loss of caveolin-3 induced by the dystrophy-associated P104L mutation impairs L-type calcium channel function in mouse skeletal muscle cells.
Couchoux H; Allard B; Legrand C; Jacquemond V; Berthier C
J Physiol; 2007 May; 580(Pt.3):745-54. PubMed ID: 17317753
[TBL] [Abstract][Full Text] [Related]
16. Myostatin signaling through Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism.
Zhu X; Topouzis S; Liang LF; Stotish RL
Cytokine; 2004 Jun; 26(6):262-72. PubMed ID: 15183844
[TBL] [Abstract][Full Text] [Related]
17. Caveolin-3 is a direct molecular partner of the Cav1.1 subunit of the skeletal muscle L-type calcium channel.
Couchoux H; Bichraoui H; Chouabe C; Altafaj X; Bonvallet R; Allard B; Ronjat M; Berthier C
Int J Biochem Cell Biol; 2011 May; 43(5):713-20. PubMed ID: 21262376
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of P104L mutant caveolin-3 in mice develops hypertrophic cardiomyopathy with enhanced contractility in association with increased endothelial nitric oxide synthase activity.
Ohsawa Y; Toko H; Katsura M; Morimoto K; Yamada H; Ichikawa Y; Murakami T; Ohkuma S; Komuro I; Sunada Y
Hum Mol Genet; 2004 Jan; 13(2):151-7. PubMed ID: 14645200
[TBL] [Abstract][Full Text] [Related]
19. The possible role of myostatin in skeletal muscle atrophy and cachexia.
Jespersen J; Kjaer M; Schjerling P
Scand J Med Sci Sports; 2006 Apr; 16(2):74-82. PubMed ID: 16533345
[TBL] [Abstract][Full Text] [Related]
20. AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency.
Bartoli M; Poupiot J; Vulin A; Fougerousse F; Arandel L; Daniele N; Roudaut C; Noulet F; Garcia L; Danos O; Richard I
Gene Ther; 2007 May; 14(9):733-40. PubMed ID: 17330087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
